CMS is adding value-based care (VBC) risk faster than many providers can build the data and tech capacity they need to succeed.
|Podcasts|August 10, 2022
Reducing Health Care Disparities Starts at the Top, Says Dr Sachin Jain
In this episode of Managed Care Cast, we speak with Sachin Jain, MD, MBA, SCAN Group and Health Plan's president and CEO, about how the organization made 10% of senior managers’ annual bonuses dependent on how well the gap in medication adherence among diverse populations was reduced.
Advertisement
Even before the pandemic began in 2020, the number of health care organizations appointing chief health equity officers had started to grow. Is this a role for 1 person only or do initiatives to tackle health care disparities and other issues begin at a higher level? And how can change really be accomplished so there is a measurable effect on health outcomes?
In this episode of Managed Care Cast, we speak with Sachin Jain, MD, MBA, who joined SCAN Group and Health Plan 2 years ago as president and CEO. He discusses an effort, recently described in an article in
The former CareMore executive shares why executives at the top of organizations need to champion and lead initiatives to reduce health care disparities and do more than “virtue signaling” on health equity issues.
Listen to the interview above or through one of these podcast services:
Advertisement
Related to this article
FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs
A traditional Medicare out-of-pocket (OOP) cap could reduce beneficiaries’ costs but increase annual federal spending by $39 billion to $96 billion.
Build scalable obesity care with multidisciplinary teams, clear triage, and monitoring protocols; address GLP-1 gaps, Medicare access and price barriers, including oral GLP-1.
Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.
The article explores the use of dose-intensive IV iron replacement to achieve long-term hemoglobin stability in patients with moderate to severe HHT-related bleeding. The approach recognizes what the author calls "the relentless and recurrent nature of HHT-associated bleeding," and may help patients achieve better quality of life.
CMS finalized the mandatory GLOBE Model, tying Part B drug rebates to international prices in areas covering 25% of beneficiaries from Jan. 1, 2027.
CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.
Advertisement
Advertisement
Trending on AJMC
1
Pipeline Advances in Sjögren Disease Bring Targeted Therapies Closer
2
VBC Risk Is Outpacing Provider Readiness, CMS Must Act
3
Systemic Sclerosis Linked to Dramatic Rise in Lung Cancer Risk
4
VYD2311 Shows Superior Safety vs mRNA COVID-19 Vaccine
5